Amneal Launches Alymsys (biosimilar, bevacizumab) in the US

Share this

Amneal Launches Alymsys (biosimilar, bevacizumab) in the US


  • The company launches Alymsys, a biosimilar referencing Avastin to provide additional access and options to patients and physicians for affordable oncology treatments
  • Alymsys is a vascular endothelial growth factor inhibitor used in oncology that was developed by mAbxience with an experience in the development, manufacture, and commercialization of biopharmaceuticals
  • Additionally, the company also seeks to increase the number of molecules in its biosimilar portfolio and has a growing line of branded pharmaceutical products with a primary focus on endocrine and central nervous system disorders

Ref: Businesswire | Image: Amneal

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions